Product Description
For dyslipidemia and Type II Diabetes
Mechanisms of Action: AMPK Binder, HMG-CoA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yuhan
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|Dyslipidemia
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02125227 |
YH14755-102 | P1 |
Completed |
Healthy Volunteers |
2014-09-01 |
2025-08-27 |
||
NCT02586129 |
YH14755-301 | P3 |
Completed |
Dyslipidemia|Type 2 Diabetes |
2017-07-07 |
2019-03-20 |
Recent News Events
Date |
Type |
Title |
|---|